Acticor Biotech SAS
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALACT.PA research report →
About the company
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke.
- CEO
- Gilles Avenard
- IPO
- 2021
- Employees
- 31
- HQ
- Paris, FR
Price Chart
- Market Cap
- $3.94M
- P/E
- -166.67
- P/S
- 0.00
- P/B
- -0.57
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 493.38%
- ROIC
- -1849.66%
- Revenue
- $0 · 0.00%
- Net Income
- $-18,640,000 · -17.40%
- EPS
- $-0.00 · 99.90%
- Op Income
- $-20,163,000
- FCF YoY
- -7.67%
- 52W High
- $5.30
- 52W Low
- $0.22
- 50D MA
- $0.25
- 200D MA
- $0.46
- Beta
- -0.26
- Avg Volume
- 6.84K
Get TickerSpark's AI analysis on ALACT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALACT.PA coverage
Recent articles, reports, and earnings notes.
No research on ALACT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALACT.PA report →Similar companies
Peers in the same neighborhood.